Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director | June 03, 2024 | June 04, 2024 |
| PALVELLA THERAPEUTICS, INC.PVLA · Entity 4452 | Director | June 10, 2026 | June 12, 2026 |
| Vaxart, Inc.VXRT · Entity 6654 | Director | July 16, 2026 | July 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date June 03, 2024 · Filed June 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 97,720 |
Ending reported balance
After 2024-06-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-06-03 · Exercise / conversion · Acquired 5,047 · Balance 101,888 Row 2 · 2024-06-03 · Tax withholding · Disposed 4,168 · Balance 97,720 |
| Stock Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $63.10 · Expires 2024-06-03 | Direct | 0 |
Reported balance
After 2024-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-03 · Exercise / conversion · Disposed 5,047 · Balance 0 F1: Reflects the number of options outstanding after the transactions from this specific stock option grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the number of options outstanding after the transactions from this specific stock option grant.
PALVELLA THERAPEUTICS, INC.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $102.19 · Expires 2036-06-10 | Direct | 3,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 3,000 · Balance 3,000 F1: The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date.
Vaxart, Inc.
Report date July 16, 2026 · Filed July 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 135,966 |
Reported balance
After 2026-07-16 transaction · row 1
1 source rowRow 1 · 2026-07-16 · Grant · Acquired 39,400 · Balance 135,966 F1: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary date of the grant. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.51 · Expires 2036-07-16 | Direct | 78,700 |
Reported balance
After 2026-07-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-16 · Grant · Acquired 78,700 · Balance 78,700 F2: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary date of the grant.
F2: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary of the date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2026 Filed Jul 18, 2026 01:50 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Options (right to buy) · Derivative | 78,700 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001437749-26-023809 · rdgdoc.xml · derivative · entry 2 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,700 Underlying: Common Stock · 78,700 shares Expires 2036-07-16 F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary of the date of the grant. Read SEC document |
| July 16, 2026 Filed Jul 18, 2026 01:50 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 39,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-023809 · rdgdoc.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,966 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary date of the grant. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:06 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $102.19 | $0.00 |
DisclosureSEC source: 0001104659-26-073437 · tm2617372-4_4seq1.xml · derivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 13:00 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | PurchaseCommon Stock | 2,400 | $125.00 | $300,000.00 |
DisclosureSEC source: 0001104659-26-021921 · tm267613-1_4seq1.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,812 F1 · shares: Represents shares of common stock purchased in the underwritten offering of Palvella Therapeutics, Inc. at the offering price, which closed on February 27, 2026. Read SEC document |
| November 17, 2025 Filed Nov 21, 2025 18:21 UTC | Vaxart, Inc. VXRT · Entity 6654 | PurchaseCommon Stock | 16,783 | $0.41 | $6,797.12 |
DisclosureSEC source: 0001437749-25-035952 · rdgdoc.xml · nonDerivative · entry 2 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,566 Read SEC document |
| November 17, 2025 Filed Nov 21, 2025 18:21 UTC | Vaxart, Inc. VXRT · Entity 6654 | PurchaseCommon Stock | 23,217 | $0.39 | $9,124.28 |
DisclosureSEC source: 0001437749-25-035952 · rdgdoc.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,783 Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 01:04 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 95,400 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001437749-25-020570 · rdgdoc.xml · derivative · entry 2 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,400 Underlying: Common Stock · 95,400 shares Expires 2035-06-13 F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2026 annual meeting of stockholders of the Issuer and June 13, 2026, the first anniversary of the date of the grant. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 01:04 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-020570 · rdgdoc.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,566 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2026 annual meeting of stockholders of the Issuer and June 13, 2026, the first anniversary date of the grant. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 23:59 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,350 | $0.00 Strike: $26.23 | $0.00 |
DisclosureSEC source: 0001583648-25-000039 · edgardoc.xml · derivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,350 Underlying: Common Stock · 12,350 shares Expires 2035-06-10 Read SEC document |
| December 13, 2024 Filed Dec 18, 2024 01:46 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantStock Option (right to buy) · Derivative | 24,700 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0001062993-24-020823 · form4.xml · derivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,700 Underlying: Common Stock · 24,700 shares Expires 2034-12-13 F1 · derivative.exercise_date: The stock options will vest and become exercisable in 36 equal monthly installments through the third anniversary of the grant date. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 20:39 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 95,400 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001437749-24-020096 · rdgdoc.xml · derivative · entry 2 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,400 Underlying: Common Stock · 95,400 shares Expires 2034-06-11 F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2025 annual meeting of stockholders of the Issuer and June 11, 2025, the first anniversary of the date of the grant. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 20:39 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-020096 · rdgdoc.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,566 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2025 annual meeting of stockholders of the Issuer and June 11, 2025, the first anniversary date of the grant. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 23:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 5,047 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001048477-24-000118 · wk-form4_1717543778.xml · derivative · entry 3 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,047 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 23:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 4,168 | $76.41 | $318,476.88 |
DisclosureSEC source: 0001048477-24-000118 · wk-form4_1717543778.xml · nonDerivative · entry 2 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,720 Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 23:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 5,047 | $63.10 | $318,465.70 |
DisclosureSEC source: 0001048477-24-000118 · wk-form4_1717543778.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2024 Filed May 23, 2024 21:26 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000102 · wk-form4_1716499557.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,841 F1 · price: Restricted stock units granted on May 21, 2024. Price not applicable. Read SEC document |
| June 26, 2023 Filed Aug 2, 2023 01:20 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 41,510 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001437749-23-021505 · rdgdoc.xml · derivative · entry 2 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,510 Underlying: Common Stock · 41,510 shares Expires 2033-06-26 F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2024 annual meeting of stockholders of the Issuer and June 26, 2024, the first anniversary of the date of the grant. Read SEC document |
| June 26, 2023 Filed Aug 2, 2023 01:20 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 6,922 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-021505 · rdgdoc.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,566 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2024 annual meeting of stockholders of the Issuer and June 26, 2024, the first anniversary date of the grant. Read SEC document |
| May 23, 2023 Filed May 24, 2023 22:25 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031968 · doc4.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,121 F1 · price: Restricted stock units granted on May 23, 2023. Price not applicable. Read SEC document |
| May 12, 2023 Filed May 17, 2023 22:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 8,500 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001209191-23-030367 · doc4.xml · derivative · entry 3 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 12, 2023 Filed May 17, 2023 22:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 6,137 | $93.93 | $576,448.41 |
DisclosureSEC source: 0001209191-23-030367 · doc4.xml · nonDerivative · entry 2 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,931 Read SEC document |
| May 12, 2023 Filed May 17, 2023 22:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 8,500 | $67.81 | $576,385.00 |
DisclosureSEC source: 0001209191-23-030367 · doc4.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2022 Filed Aug 25, 2022 21:06 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 88,448 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0001437749-22-021354 · rdgdoc.xml · derivative · entry 2 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,448 Underlying: Common Stock · 88,448 shares Expires 2032-08-24 F2 · derivative.exercise_date: The shares subject to this option shall vest annually over three years from the vesting commencement date of August 25, 2022, the date of the grantee's appointment as a director of Vaxart, Inc. Read SEC document |
| August 25, 2022 Filed Aug 25, 2022 21:06 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 14,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-021354 · rdgdoc.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,644 F1 · shares: Grant of shares upon vesting of restricted stock units. One third of the shares underlying the award shall vest on each anniversary of the grant date, so that the restricted stock units would be fully vested on the third anniversary of the grant date. Read SEC document |
| May 24, 2022 Filed May 27, 2022 00:45 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011790 · doc1.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,568 F1 · price: Restricted stock units granted on May 24, 2022. Price not applicable. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 02:52 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 8,500 | $0.00 Strike: $37.46 | $0.00 |
DisclosureSEC source: 0001567619-22-005823 · doc1.xml · derivative · entry 2 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires 2022-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 02:52 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 8,500 | $37.46 | $318,410.00 |
DisclosureSEC source: 0001567619-22-005823 · doc1.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2021 Filed May 27, 2021 21:37 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 5,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011303 · doc1.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,088 F1 · price: Restricted stock units granted on May 25, 2021. Price not applicable. Read SEC document |
| October 07, 2020 Filed Oct 9, 2020 00:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 15,000 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001567619-20-017700 · doc1.xml · derivative · entry 2 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| October 07, 2020 Filed Oct 9, 2020 00:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 15,000 | $26.49 | $397,350.00 |
DisclosureSEC source: 0001567619-20-017700 · doc1.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 27, 2020 Filed May 29, 2020 20:50 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-011358 · doc1.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,968 F1 · price: Restricted stock units granted on May 27, 2020. Price not applicable. Read SEC document |
| August 07, 2019 Filed Aug 8, 2019 23:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 1,553 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001567619-19-016093 · doc1.xml · derivative · entry 2 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,047 Underlying: Common Stock · 1,553 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| August 07, 2019 Filed Aug 8, 2019 23:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 1,553 | $63.10 | $97,994.30 |
DisclosureSEC source: 0001567619-19-016093 · doc1.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 22:10 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012973 · doc1.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,115 F1 · price: Restricted stock units granted on June 4, 2019. Price not applicable. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 18:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,000 | $96.94 | $96,935.00 |
DisclosureSEC source: 0001567619-18-002256 · doc1.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,685 Read SEC document |
| June 05, 2018 Filed Jun 8, 2018 00:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-027787 · doc1.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,685 F1 · price: Restricted stock units granted on June 5, 2018. Price not applicable. Read SEC document |
| December 14, 2017 Filed Dec 19, 2017 01:56 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 800 | $88.90 | $71,116.00 |
DisclosureSEC source: 0001140361-17-046612 · doc1.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,385 F1 · price: All shares sold at the same price. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (right to buy) Common Stock · Derivative | 4,910 | $0.00 Strike: $89.60 | $0.00 |
DisclosureSEC source: 0001140361-17-024504 · doc1.xml · derivative · entry 2 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,910 Underlying: Common Stock · 4,910 shares Expires 2027-06-05 F2 · derivative.exercise_date: Option grant vests in full on June 6, 2018. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 2,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-024504 · doc1.xml · nonDerivative · entry 1 HERON ELAINE J · CIK 0001235471 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,185 F1 · price: Restricted stock units granted on June 6, 2017. Price not applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.